TGFB1 and neoplasm: Recent advances include engineering CAR T cells with chimeric switch receptors that convert inhibitory TGF-β signals into activating ones, along with secreting TGF-β traps that neutralize local TGF-β levels, creating a dual mechanism to resist and overcome tumor immunosuppression [169].